Clinical trial · Interventional
PACED-digitized Support During Adjuvant Endocrine Therapy
PACED-Patient-centred Digital Support During Adjuvant Endocrine Breast Cancer Treatment
NCT05084625CI-TRIAL-00076132unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The research team want to investigate whether digital support, an app under preventive hormonal breast cancer treatment can lead to less late side effects, better quality of life and increased adherence to treatment.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Quality of Life | — | UNRESOLVED | — |
| Treatment Adherence | — | UNRESOLVED | — |
| Treatment Side Effects | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Digitized support | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm A- access to digitized support, an app
- description
- Patients in Arm A will have access to digitized support-an app for 12 months from baseline in addition to standard follow-up.
- interventionNames
- Other: Digitized support
- type
- NO_INTERVENTION
- label
- Arm B-standard follow-up
- description
- Patients in Arm B-will continue with standard follow-up from baseline and onwards
Primary outcomes (2)
- measure
- Difference between the two groups with regard to change in quality of life from baseline to 12 months measured by Questionnaires European Organisation for Research and Treatment for Cancer Quality of life C30 (EORTC QLQ C30).
- timeFrame
- Change from baseline to 12 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Hormone receptor positive breast cancer * On adjuvant endocrine treatment 0-16 weeks ago Exclusion Criteria: * Cognitively impaired * No access to a mobile phone or internet * Not understanding Swedish
References
Publications (0)
Data not yet available
No reference posted for this study.